Skip to main content
NewslettersWatchlist

Resverlogix Corp(RVX-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.0600
Day High0.0600
Open:0.0600
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
AI-generated - The Globe and Mail
Resverlogix: Top 25 Undervalued Toronto Stock Exchange Stocks (RVX)
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
Newsfile
Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
Newsfile
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
Baystreet
Stocks in play: Resverlogix Corp.
Newsfile
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
Newsfile
Resverlogix Announces Updated Annual and Special Meeting of Shareholders
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
Newsfile
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
Newsfile
Resverlogix Announces Change to Its Board of Directors
Newsfile
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)
Baystreet
Stocks in play: Resverlogix Corp.
Newsfile
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

Profile

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.